CBSC activates China manufacturing pipeline and advances MyCardia AT into final NMPA submission phase with Ebulent Medical.

Jan 15

Cardiac Biotech

Cardiac Biotech

Cardiac Biotech Solutions Activates China Production Pipeline for MyCardia AT and Moves into Final NMPA Submission Phase

CBSC activates China manufacturing pipeline and enters final NMPA submission phase for MyCardia AT cardiac monitoring device.

Dec 07

Cardiac Biotech

Cardiac Biotech

Executed Manufacturing Letter of Intent with Shenzhen Pump Medical System Co., Ltd.

Partnership to provide high-volume manufacturing capability and facilitate obtaining requisite government approvals.

How can we help you?

Contact Us

© 2020-2026. Cardiac Biotech Solutions, Inc. - All rights reserved. | Designer

Get our news in your inbox!

Join our newsletter and we will send our news directly to you.